Weave Communications, Inc. WEAV R2KR3KPHARMA
Company Overview
Weave Communications, Inc. operates an AI-powered patient communications, engagement, and payments platform for small and medium-sized healthcare businesses. It offers AI-receptionist; Unified Phone Number; Customized Phone System, a smarter phone system to identify whether incoming calls are from new or current patients, provide information at every call, and manage heavy call times; Softphones to make and receive calls from anywhere with an internet connection; Text Messaging and SMS response assistant; Missed Call Text that allows practices to respond when a call is missed; Missed Text Auto-Reply that replies to patient text messages by automatically responding to messages received outside of a practice's normal operating hours; Team Chat, a group messaging solution; and Weave Mobile App. It also provides Weave Reviews and Respond Assistant to request, collect, monitor, and respond to reviews; Weave Email Marketing and Email Assistant to create professional emails; Text Connect to interact with their patients online directly through their websites; and Weave Payments, a payment processing solution. The company provides Weave Digital Forms to collect patient information; Online Scheduling that allows patients to request appointments from the practice's website, send automatic scheduling reminders, and personalize each reminder for the patient; Insurance Eligibility, an insurance tool; Insurance Verification; Practice Analytics that provides real-time data on patient retention, appointment scheduling, treatment acceptance rates, and revenue generation; Call Intelligence; and Weave Enterprise for multi-location healthcare practices comprising dental service organizations, vision, veterinary, and medical groups. The company was formerly known as Recall Solutions, LLC and changed its name to Weave Communications, Inc. in October 2015. Weave Communications, Inc. was founded in 2008 and is headquartered in Lehi, Utah.
Why Investors Should Care
Revenue has grown at a 39.2% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $239.02M (+17.0% YoY); net profit $-28.05M.
- Trailing 12 Months Year-on-year growth — revenue +15.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 39.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 39.19% |
| 1 Year: | 15.50% |
Stock Price Performance
| 1 Year: | -8.42% |
| 6 Months: | +51.95% |
| 3 Months: | +11.28% |
| 1 Month: | +0.82% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)62.73 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 39.2% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | WEAV Weave Communications, Inc. R2KR3KPHARMA | 7.40 | -27.41 | $592.10M | 0.00% | -24.81% | -25.08% | 39.19% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.39M | 25.67M | - | 30.30M | - | 33.27M | - | - | - | - | - | - | - | - | 55.81M | 58.47M | 61.34M | 63.40M | 65.50M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.86M | 16.52M | 17.00M | 17.33M | 17.96M | - |
| Gross Profit | 12.17M | 14.87M | 16.04M | 17.43M | - | 19.52M | 21.18M | 23.21M | 26.53M | 28.04M | 29.93M | 32.99M | 36.12M | 37.73M | 39.95M | 41.95M | 44.34M | 46.07M | 47.54M | 48.65M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 49.27M | 52.14M | 53.29M | 48.23M | 53.56M | - |
| Operating Income | -10.15M | -8.71M | -14.13M | -13.90M | - | -13.51M | -14.59M | -11.86M | -8.52M | -9.83M | -8.02M | -8.15M | -9.26M | -6.63M | -9.32M | -10.19M | -8.94M | -2.16M | -6.02M | -4.39M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.57M | -5.26M | -3.95M | 3.00M | -772.00K | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 397.00K | 537.00K | 366.00K | 400.00K | 369.00K | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.75M | -9.82M | -8.59M | -1.82M | -5.67M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 71.00K | -1.11M | 82.00K | 29.00K | 102.00K | - |
| Net Income | -10.40M | -8.98M | -14.42M | -14.22M | - | -13.84M | -14.81M | -11.82M | -7.86M | -8.99M | -7.14M | -7.20M | -8.55M | -5.88M | -8.82M | -8.71M | -8.67M | -1.85M | -5.77M | -4.26M |
| Diluted EPS | -0.95 | -0.79 | -1.12 | -1.03 | -2.60 | -0.21 | -0.23 | -0.18 | -0.12 | -0.13 | -0.10 | -0.10 | -0.12 | -0.08 | -0.12 | -0.11 | -0.11 | -0.02 | -0.07 | -0.05 |
| R&D Expense | 5.41M | 5.84M | 7.87M | 6.18M | - | 7.20M | 7.43M | 7.90M | 7.69M | 8.59M | 8.63M | 9.64M | 9.96M | 9.87M | 11.15M | 11.99M | 13.12M | - | 10.81M | 12.05M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 45.75M | 79.90M | - | 142.12M | 170.47M | 204.31M | 239.02M |
| Cost of Revenue | - | - | - | 53.28M | 54.38M | 58.43M | 66.72M |
| Gross Profit | 27.23M | 45.45M | - | 88.84M | 116.09M | 145.88M | 172.31M |
| Operating Expenses | - | - | - | 138.54M | 150.46M | 177.29M | 202.92M |
| Operating Income | -31.92M | -39.57M | - | -49.70M | -34.37M | -31.41M | -30.61M |
| EBITDA | - | - | - | -31.55M | -13.02M | -11.17M | -10.78M |
| Interest Expense | - | - | - | 1.44M | 1.92M | 1.52M | 1.70M |
| Pretax Income | - | - | - | -49.63M | -30.77M | -28.16M | -28.98M |
| Tax Provision | - | - | - | 104.00K | 260.00K | 189.00K | -924.00K |
| Net Income | -32.06M | -40.42M | - | -49.74M | -31.03M | -28.35M | -28.05M |
| Diluted EPS | -3.30 | -3.75 | - | -0.76 | -0.46 | -0.40 | -0.37 |
| R&D Expense | 14.41M | 19.97M | 27.01M | 30.71M | 34.04M | 40.23M | 44.46M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 92.97M | - | 208.35M | 201.01M | 188.93M | 207.97M |
| Current Assets | - | - | - | - | 132.89M | 129.78M | 120.74M | 104.99M |
| Cash & Equivalents | - | - | 55.70M | - | 62.00M | 50.76M | 51.60M | 54.96M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 3.30M | 3.51M | 3.74M | 4.35M |
| Total Liabilities | - | - | 54.98M | - | 125.13M | 122.06M | 121.96M | 125.58M |
| Current Liabilities | - | - | 44.02M | - | 72.22M | 72.85M | 76.62M | 84.60M |
| Long Term Debt | - | - | 3.60M | 10.00M | - | - | - | - |
| Total Debt | - | - | - | - | 73.56M | 59.54M | 56.06M | 52.15M |
| Total Equity | -61.91M | -85.99M | -113.94M | - | 83.22M | 78.96M | 66.97M | 82.38M |
| Shares Outstanding | - | - | - | - | 65.74M | 70.12M | 73.23M | 78.35M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -22.07M | -15.52M | - | -12.77M | 10.22M | 14.15M | 17.54M |
| Investing Cash Flow | -2.47M | -3.86M | - | -54.03M | -7.74M | 8.88M | -6.85M |
| Financing Cash Flow | 65.00M | -5.15M | - | -7.21M | -13.72M | -22.19M | -7.33M |
| Capital Expenditure | -2.47M | -2.76M | - | -3.13M | -3.69M | -3.79M | -4.68M |
| Free Cash Flow | -24.54M | -18.28M | - | -15.89M | 6.53M | 10.36M | 12.86M |
| Net Change in Cash | - | - | - | -74.00M | -11.24M | 840.00K | 3.36M |
| Share Buybacks | 1.41M | 0 | 0 | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | 59.5% | 56.9% | - | 62.5% | 68.1% | 71.4% | 72.1% |
| Operating Margin % | -69.8% | -49.5% | - | -35.0% | -20.2% | -15.4% | -12.8% |
| Net Margin % | -70.1% | -50.6% | - | -35.0% | -18.2% | -13.9% | -11.7% |
| ROE % | 37.3% | 35.5% | - | -59.8% | -39.3% | -42.3% | -34.1% |
| ROCE % | - | -80.8% | - | -36.5% | -26.8% | -28.0% | -24.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Newtyn Management, Llc | 8.49% | 6.79M | $50.11M |
| 2 | Blackrock Inc. | 6.64% | 5.31M | $39.19M |
| 3 | Crosslink Capital Inc | 5.34% | 4.27M | $31.53M |
| 4 | Disciplined Growth Investors, Inc. | 3.75% | 3.00M | $22.13M |
| 5 | Vanguard Capital Management LLC | 3.64% | 2.91M | $21.50M |
| 6 | Vanguard Portfolio Management LLC | 3.47% | 2.78M | $20.48M |
| 7 | Marshall Wace LLP | 3.12% | 2.49M | $18.40M |
| 8 | Frontier Capital Management Company LLC | 3.06% | 2.45M | $18.05M |
| 9 | Gumshoe Capital Management LLC | 2.70% | 2.16M | $15.93M |
| 10 | State Street Corporation | 2.54% | 2.03M | $14.98M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for WEAV
Weave Communications, Inc. (WEAV) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE9Yd21uZ2FDc1JpcEVQbHI1eVQ5YUxUcDl3SDFiSnlKeEw0OGNCa1VUSUNzaE9yX29VTjFNWk8wc1dCTUl0bGpFSFNVQkVRR2ZfVnc?oc=5" target="_blank">Weave Communications, Inc. (WEAV) Stock Price, News, Quo…
Weave Communications, Inc. (WEAV) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE9MdFRiR3M5anhhNEp0V1ZsZ3B0dkFXX2w0YThEQXBEeVczZEtHWlFaek84M1ZCM3dDX0xhbjVNWTVLUUF1TGtKVU5TX0tuWWpQZVE?oc=5" target="_blank">Weave Communications, Inc. (WEAV) stock price, news, quo…
Weave Communications, Inc.(NYSE:WEAV) dropped from Russell Small Cap Comp Growth Benchmark - www.marketscreener.com
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxQT1FhYlc0WHBJX19mbkFaOUpjWFBPZ3RFcE9td2tJcEZQS1VORGNPOXdtOXFtY3phVnRHYk9xRzNLSXRyZWVQRVJ2QWJXWjVRdkRQLVgyR1h4eldPekZVVzZNSDRlRDNYYVM4bUtiSGpTSmdhaEJlS3ktaE1JaGJYcXgxR3kwSHVDZTAwVX…
Healthcare software firm Weave Communications to go private after being acquired by Francisco Partners - SiliconANGLE
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxPczRlbk45TVJ5MlViT0hvbktOR3FFek95UVlEWjhOMk5VSzhCcjFBbE8wdkxkTXkxM05XZ0V3c3dVUkNtOENlM2RXUFcxOGJEY1RSRUluYkd3Q0xaM3ZKNU01ZXJ3SnFMNnpHUk16ZkQ2NkRmQllaVFFheFpZb2RpVUlWMzFhQUJJMURNOW…
8,761 shares withheld at $7.39 cover CFO taxes at Weave Communications (WEAV). - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNN2tVdFBpYmYyOWV6c3NMa2xVTEJkd3VFZnRDUEVFSUV4ZkY0c202T0U1WjczTjBIZDN1d3dzRWtXbXJfRWpHOE1Cd2lSTXpBalNEWVFSZVVBeXZ2QncyNnVaMUVaNUpRdW9EYW5CSEdrMjR0SUdwblAwVGgzS0sxa2R3VE9EU2pQN3Z6Tk…
Why Weave Communications Stock Soared Today - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxQbXQ3N0FsZFludkFrTEltbGlLeWFYX0J2VG9mU2dVTEFVUkZhbFBOVlpQMFh2OHZBcGRXa1hFT2daVXZHc0Nob3F0WDlJd2kxRFB5LXJoN1VCSnRYU3lScldpRWJHc0NLdGptUWVOQ3Z0YmFWNW5PQ1lhb3lwTmUyTE1uQTRfX0VEa0dnaD…
WEAV — Frequently Asked Questions
What is the current share price of Weave Communications, Inc. (WEAV)?
As of 2026-10-23 16:27 PDT, Weave Communications, Inc. (WEAV) trades at $7.40 on NYSE. Its 52-week range is $4.37 to $8.08.
What is the market capitalisation of WEAV?
Weave Communications, Inc. (WEAV) has a market capitalisation of $592.10M on NYSE.
What is the P/E ratio of WEAV?
WEAV trades at a trailing price-to-earnings (P/E) ratio of -27.41. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 6.95.
What is the return on equity (ROE) of WEAV?
WEAV has a return on equity (ROE) of -25.08%. Its return on capital employed (ROCE) is -24.81%.
Is WEAV a good stock to buy?
This page provides a data-driven analysis of Weave Communications, Inc. (WEAV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.